A detailed history of Provenance Wealth Advisors, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Provenance Wealth Advisors, LLC holds 105 shares of LLY stock, worth $107,278. This represents 0.01% of its overall portfolio holdings.

Number of Shares
105
Previous 237 55.7%
Holding current value
$107,278
Previous $196 Million 59.07%
% of portfolio
0.01%
Previous 0.03%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

SELL
$625.65 - $812.69 $82,585 - $107,275
-132 Reduced 55.7%
105 $80.1 Million
Q1 2025

Aug 15, 2025

SELL
$725.72 - $929.72 $85,634 - $109,706
-118 Reduced 33.24%
237 $196 Million
Q1 2024

Aug 15, 2025

SELL
$592.2 - $792.28 $3,553 - $4,753
-6 Reduced 1.66%
355 $276 Million
Q4 2023

Aug 15, 2025

BUY
$525.19 - $619.13 $3,151 - $3,714
6 Added 1.69%
361 $210 Million
Q3 2023

Aug 15, 2025

BUY
$434.7 - $599.3 $154,318 - $212,751
355 New
355 $191 Million

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $971B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Provenance Wealth Advisors, LLC Portfolio

Follow Provenance Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Provenance Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Provenance Wealth Advisors, LLC with notifications on news.